Skip to Content

Melflufen Is Safe and Effective in Patients with Alkylator-Refractory Disease

Fredrik Schjesvold gives his insights into the OCEAN trial, which investigates melflufen’s role in refractory multiple myeloma by comparing pomalidomide-dexamethasone with melflufen-dexamethasone in refractory cases.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top